How, Jonathan <br/><br/>
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.  [electronic resource] 

 -  Leukemia & lymphoma  2015 
 - 2793-802 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2015.1018248  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Azacitidine--administration & dosage<br/>Decitabine<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Female<br/>Histone Deacetylase Inhibitors--administration & dosage<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Recurrence<br/>Remission Induction<br/>Retreatment<br/>Treatment Outcome<br/>Vorinostat